World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
88
Citations
26024
World Ranking
13249
National Ranking
6748

Xuemei Wang publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Xuemei Wang sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 463 publications — 51st percentile

51% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Xuemei Wang D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Xuemei Wang sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 88 D-Index — 36th percentile

36% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Xuemei Wang is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on medical and oncological fields, contributing extensively to several subfields such as pulmonary and respiratory medicine, hematology, oncology, surgery, and genetics.

The main topics of Wang's work include acute myeloid leukemia research, gastric cancer management and outcomes, chronic lymphocytic leukemia research, prostate cancer treatment and research, chronic myeloid leukemia treatments, prostate cancer diagnosis and treatment, and colorectal cancer treatments and studies.

Wang has published numerous papers in high-profile journals. Some selected recent publications are:

  • Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study, 2021, Journal for ImmunoTherapy of Cancer
  • Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia, 2022, Journal of Clinical Oncology
  • Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia, 2021, JAMA Oncology
  • Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy, 2022, Blood Cancer Journal
  • The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development, 2020, Clinical Cancer Research

Wang collaborates frequently with several other researchers, including:

  • Hagop M. Kantarjian
  • Tapan M. Kadia
  • Naveen Pemmaraju
  • Nitin Jain
  • Courtney D. DiNardo

Their work is often published in journals such as Blood, Journal of Clinical Oncology, American Journal of Hematology, The Journal of Urology, and Oncology.

Wang has contributed significantly to the field of medicine, with 247 publications primarily related to their main area of expertise. The subfields reflect focused investigations into respiratory and hematologic conditions, surgical interventions, and genetic factors influencing disease.

Best Publications

  • Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation

    Sergio Giralt;Peter F. Thall;Issa Khouri;Xuemei Wang

  • Body surface area and body weight predict total liver volume in Western adults

    Jean Nicolas Vauthey;Eddie K. Abdalla;Dorota A. Doherty;Philippe Gertsch

  • Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS

    Marcos de Lima;Daniel Couriel;Peter F. Thall;Xuemei Wang

  • Phase I Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Solid Tumors With Observations in Androgen-Independent Prostate Cancer

    Christos N. Papandreou;Danai D. Daliani;Darrell Nix;Hong Yang

  • Ibrutinib and venetoclax for first-line treatment of CLL

    Nitin Jain;Michael Keating;Philip Thompson;Alessandra Ferrajoli

  • Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.

    William G. Wierda;Susan O'Brien;Xuemei Wang;Stefan Faderl

  • Fingerprinting the circulating repertoire of antibodies from cancer patients

    Paul J. Mintz;Jeri Kim;Kim Anh Do;Xuemei Wang

  • Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility.

    Milena S. Nicoloso;Hao Sun;Hao Sun;Riccardo Spizzo;Hyunsoo Kim

  • Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma.

    Melanie B. Thomas;Romil Chadha;Katrina Glover;Xuemei Wang

  • PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors

    Filip Janku;Apostolia Maria Tsimberidou;Ignacio Garrido-Laguna;Xuemei Wang

  • Presalvage prostate-specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy.

    Philippe E. Spiess;Andrew K. Lee;Dan Leibovici;Xuemei Wang

  • The Crosstalk of mTOR/S6K1 and Hedgehog Pathways

    Yan Wang;Qingqing Ding;Chia Jui Yen;Weiya Xia

  • Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non–Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial

    Nizar M. Tannir;Eric Jonasch;Laurence Albiges;Emre Altinmakas

  • Guidelines for Reporting of Statistics for Clinical Research in Urology.

    Melissa Assel;Daniel Sjoberg;Andrew Elders;Xuemei Wang

  • High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation.

    Stefan O. Ciurea;Marcos J.G. de Lima;Pedro Cano;Martin Korbling

  • Results of a Phase II Study With Doxorubicin, Etoposide, and Cisplatin in Patients With Fully Characterized Small-Cell Carcinoma of the Prostate

    Christos N. Papandreou;Danai D. Daliani;Peter F. Thall;Shi Ming Tu

  • Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor

    Min S. Park;Shreyaskumar R. Patel;Joseph A. Ludwig;Jonathan C. Trent

  • Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia.

    Borje S. Andersson;Peter F. Thall;Timothy Madden;Daniel Couriel

  • Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers

    Ana M. Aparicio;Li Shen;Elsa M Li Ning Tapia;Jing-Fang Lu

  • Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance

    Taghi Manshouri;Kim Anh Do;Xuemei Wang;Francis J. Giles

Frequent Co-Authors

Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Alessandra Ferrajoli
Alessandra Ferrajoli The University of Texas MD Anderson Cancer Center
William G. Wierda
William G. Wierda The University of Texas MD Anderson Cancer Center
Jorge E. Cortes
Jorge E. Cortes Augusta University
Michael J. Keating
Michael J. Keating The University of Texas MD Anderson Cancer Center
Susan O'Brien
Susan O'Brien University of California, Irvine
Zeev Estrov
Zeev Estrov The University of Texas MD Anderson Cancer Center
Jaffer A. Ajani
Jaffer A. Ajani The University of Texas MD Anderson Cancer Center
Guillermo Garcia-Manero
Guillermo Garcia-Manero The University of Texas MD Anderson Cancer Center
Gautam Borthakur
Gautam Borthakur The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine often means exploring versatile pathways and continued education options. Many students are now turning to online programs for added flexibility and diverse opportunities within the healthcare field.

For those interested in healthcare administration, top cahme-accredited mha programs offer rigorous online curricula and accreditation, essential for leadership roles in hospitals and clinics.

Nurses seeking to advance their credentials can look into online rn to bsn programs without clinicals. These options are ideal for working professionals who want to deepen their knowledge without the additional scheduling challenges of in-person clinical rotations.

Aspiring nurse practitioners and leaders might consider the fastest online dnp programs, enabling them to reach the highest level of nursing practice in less time.

For those who prefer a more streamlined doctoral experience, some dnp programs without dissertation offer an accelerated path, focusing on practical leadership rather than traditional research.

Best Scientists Citing Xuemei Wang

Trending Scientists

Recently Published Articles